share_log

Weak Statutory Earnings May Not Tell The Whole Story For Baolingbao BiologyLtd (SZSE:002286)

Weak Statutory Earnings May Not Tell The Whole Story For Baolingbao BiologyLtd (SZSE:002286)

疲软的法定收入可能无法说明宝灵宝生物有限公司(深圳证券交易所:002286)的全部情况
Simply Wall St ·  05/06 02:57

The subdued market reaction suggests that Baolingbao Biology Co.,Ltd.'s (SZSE:002286) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.

疲软的市场反应表明,宝灵宝生物有限公司, Ltd. 's(深圳证券交易所:002286)最近的财报没有任何意外。我们的分析表明,除了疲软的利润数字外,投资者还应意识到这些数字中的其他一些潜在弱点。

earnings-and-revenue-history
SZSE:002286 Earnings and Revenue History May 6th 2024
SZSE: 002286 收益和收入历史记录 2024 年 5 月 6 日

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

To properly understand Baolingbao BiologyLtd's profit results, we need to consider the CN¥24m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. We can see that Baolingbao BiologyLtd's positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

为了正确理解宝灵宝生物有限公司的利润业绩,我们需要考虑不寻常项目带来的2400万元人民币的收益。虽然获得更高的利润总是件好事,但来自不寻常物品的巨额捐款有时会抑制我们的热情。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。而且,毕竟,这正是会计术语的含义。我们可以看到,截至2024年3月的一年中,宝灵宝生物有限公司的正面不寻常项目与其利润相比相当可观。在其他条件相同的情况下,这可能会使法定利润成为衡量潜在盈利能力的不良指导。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Baolingbao BiologyLtd.

注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对宝灵宝生物有限公司的资产负债表分析。

Our Take On Baolingbao BiologyLtd's Profit Performance

我们对宝灵宝生物有限公司盈利表现的看法

As we discussed above, we think the significant positive unusual item makes Baolingbao BiologyLtd's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Baolingbao BiologyLtd's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 37% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Baolingbao BiologyLtd as a business, it's important to be aware of any risks it's facing. For example - Baolingbao BiologyLtd has 3 warning signs we think you should be aware of.

正如我们上面讨论的那样,我们认为这一重大利好不寻常的项目使宝灵宝生物有限公司的收益无法衡量其潜在盈利能力。因此,我们认为宝灵宝生物有限公司的潜在盈利能力很可能低于其法定利润。但是,至少持有人可以从过去三年的每股收益每年增长37%中得到一些安慰。当然,我们只是在分析其收益时才浮出水面;人们还可以考虑利润率、预测增长和投资回报率等因素。如果您想进一步了解宝灵宝生物有限公司作为一家企业,请务必了解其面临的任何风险。例如,宝灵宝生物有限公司有3个警告标志,我们认为你应该注意。

Today we've zoomed in on a single data point to better understand the nature of Baolingbao BiologyLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我们放大了单一数据点,以更好地了解宝灵宝生物有限公司利润的性质。但是,还有很多其他方法可以让你对公司的看法。有些人认为高股本回报率是优质业务的好兆头。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发